Business
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing...
About this update from Oruka Therapeutics, Inc.
[{"type":"image","alt":"Oruka Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Oruka Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/08c71a601d6ce82817d03b992189e527"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2hiA1_Fj4oqG4V.nykQQVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/08c71a601d6ce82817d03b992189e527","width":300,"height":102}},"lazy":false},{"type":"text","content":"MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026.","length":432,"tagName":"p"},{"type":"text","content":"Presentation DetailsDate: Thursday, January 15th, 2026Time: 9:00 AM PT","length":72,"tagName":"p"},{"type":"text","content":"A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations.","length":159,"tagName":"p"},{"type":"text","content":"About Oruka Therapeutics","length":24,"tagName":"p"},{"type":"text","content":"Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.","length":688,"tagName":"p"},{"type":"text","content":"Investor Contact: Alan Lada (650)-606-7911 [email protected]","length":82,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"}]